FLT3 and acute myeloid leukemia: R/R AML patients receive potentially cardiotoxic drugs [5,6,7,8,9], such as anthracyclines [4,10,11], which may cause anthracycline-related left ventricular dysfunction [8,12], and drugs leading to QT interval prolongation (QTc) [13] (e.g., FLT3 inhibitors [14,15,16], or IDH inhibitors [17,18], among others) [11,19,20,21,22].